137 Results for "

integrin-beta-1

" in MedChemExpress (MCE) Product Catalog:
Products (137)

137 Results for "integrin-beta-1" in MCE Product Catalog:

74
74 Publications Verification
Cat. No.: HY-16141
CAS No.: 188968-51-6
Synonyms: EMD 121974
Cilengitide (EMD 121974) is a BBB-permeable integrins antagonist with IC50s of 0.61 nM (ανβ3), 8.4 nM (ανβ5) and 14.9 nM (α5β1), respectively. Cilengitide inhibits the binding of ανβ3 and ανβ5 to Vitronectin with IC50s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers .
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-100506
CAS No.: 1320346-97-1
Purity:  99.43%
Target:  

Integrin

Research Areas:  

Cancer

GLPG0187 is a broad spectrum integrin receptor antagonist with antitumor activity; inhibits αvβ1-integrin with an IC50 of 1.3 nM . GLPG0187 inhibits migrasome biogenesis without cytotoxicity .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-13535
CAS No.: 262438-43-7
Target:  

Integrin

Research Areas:  

Cancer

ATN-161 is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-13535A
CAS No.: 904763-27-5
Purity:  99.04%
Synonyms: ATN-161 TFA salt
Target:  

Integrin

Research Areas:  

Cancer

ATN-161 trifluoroacetate salt is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-18644
CAS No.: 1564286-55-0
Target:  

Integrin

Research Areas:  

Cancer

CWHM-12 is a potent inhibitor of αV integrins with IC50s of 0.2, 0.8, 1.5, and 1.8 nM for αvβ8, αvβ3, αvβ6, and αvβ1.
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-P1740
CAS No.: 114681-65-1
Target:  

Integrin Apoptosis Caspase

Research Areas:  

Inflammation/Immunology

RGD peptide (GRGDNP) is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) plays an important role in cell adhesion, migration, growth, and differentiation .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-P1740A
Target:  

Integrin Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

RGD peptide (GRGDNP) TFA is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) TFA competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) TFA promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) TFA plays an important role in cell adhesion, migration, growth, and differentiation .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-100445A
Purity:  98.28%
Target:  

Integrin

Research Areas:  

Cardiovascular Disease Cancer

αvβ1 integrin-IN-1 TFA (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. Antifibrotic effects .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-100445
CAS No.: 1689540-62-2
Purity:  99.51%
Target:  

Integrin

Research Areas:  

Cardiovascular Disease Cancer

αvβ1 integrin-IN-1 (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. Antifibrotic effects .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-15102
CAS No.: 227963-15-7
Purity:  99.50%
Synonyms: L-000845704
Target:  

Integrin

Research Areas:  

Inflammation/Immunology Cancer

MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1, respectively .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-13306
CAS No.: 1228445-38-2
Purity:  99.71%
Target:  

Integrin

Research Areas:  

Metabolic Disease

Pyrintegrin is an β1-integrin agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival. Pyrintegrin enhances cell-extracellular matrix (ECM) adhesion-mediated integrin signaling. Pyrintegrin can be used as a podocyte-protective agent and has robustly adipogenic .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-14951
CAS No.: 402567-16-2
Purity:  99.75%
Synonyms: SB 683699
Target:  

Integrin

Research Areas:  

Neurological Disease

Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-15770
CAS No.: 232271-19-1
Purity:  98.06%
Target:  

Integrin

Research Areas:  

Inflammation/Immunology

TR-14035 is a orally active dual α4β74β1 integrin antagonist, with IC50 s of 7 nM and 87 nM for α4β7 and α4β1, respectively. TR-14035 can be used for the research of inflammation and autoimmune diseases .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P1408
CAS No.: 404882-00-4
Target:  

Integrin VEGFR

Research Areas:  

Cancer

Obtustatin is a non-RGD disintegrin consisting of 41 residues. Obtustatin inhibits the adhesion of α1β1 integrin to type IV Collagen (HY-NP003), blocks α1β1 integrin signaling in endothelial cells, and suppresses FGF2-induced angiogenesis. Obtustatin inhibits tumor progression in mouse models and upregulates VEGF expression in sarcoma-bearing mice. Obtustatin can be used in research related to Lewis lung carcinoma and S-180 sarcoma .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P1408A
Target:  

Integrin

Research Areas:  

Cancer

Obtustatin triacetate is a 41-residue non-RGD disintegrin. Obtustatin triacetate can be isolated from the venom of Vipera lebetina obtusa. Obtustatin triacetate is a potent and selective inhibitor of integrin α1β1 adhesion to type IV collagen. Obtustatin triacetate inhibits angiogenesis and may be used in cancer research .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P1868
CAS No.: 134580-64-6
Synonyms: DGEA peptide
Target:  

Integrin

Research Areas:  

Infection

α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P1868A
Synonyms: DGEA peptide TFA
Target:  

Integrin

Research Areas:  

Others

α2β1 Integrin Ligand Peptide TFA interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-137561
CAS No.: 2376257-44-0
Purity:  99.67%
Synonyms: PLN-74809
Target:  

Integrin

Research Areas:  

Inflammation/Immunology

Bexotegrast (PLN-74809) is an orally active, potent dual αvβ6/αvβ1 integrin inhibitor with Kd of 5.7 nM and 3.4 nM, respectively. Bexotegrast inhibits αvβ6- and αvβ1-induced TGF-β activation with IC50 values of 29.8 nM and 19.2 nM, respectively. Bexotegrast has antifibrogenic effects and block multiple avenues of TGF-β activation in the fibrotic lung .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-107588
CAS No.: 916734-43-5
Purity:  99.94%
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

TC-I 15 (TC-I-15) is a type of allosteric collagen-binding integrin α2β1 inhibitor, and it also inhibits α1β1 and α11β1. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition. TC-I 15 prevents the formation of a pre-metastatic microenvironment by inhibiting the uptake of cancer-associated fibroblast (CAF) extracellular vesicles (EVs) by lung fibroblasts, which reduces the metastasis of salivary gland adenocystic carcinoma (SACC) to the lungs in mouse models, .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-108831
CAS No.: 189261-10-7
Purity:  99.10%
Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses .
loading...
    loading...